Published: 2019-05-24

A comparative study of lipid profile in smokers and non smokers between 30 to 40 years and prediction of 10 years risk of cardiovascular disease based on Framingham scores

Mithun M., Dhandapani ., Venkatraman ., Arun Daniel J.


Background: Atherosclerosis has been described as a lipid driven inflammatory disorder of the arterial wall. Smoking is one of the most common modifiable risk factors for atherosclerosis and is the major epidemiological factor in increasing morbidity and mortality of chronic heart diseases (CHD). The objectives of this study were based on to estimate the status of lipid profile in both smokers and non-smokers and compare with each other, to predict the 10 years risk of cardiovascular risk based on Framingham score in smokers and non-smokers.

Methods: This retrospective, case-control study was conducted among 50 smokers (cases) and 50 normal individuals (controls) attending to the department of medicine during the period between December 2016 and May 2018. The socio-demographic data and clinical history was obtained using a semi-structured questionnaire and then patients were subjected to blood investigations including estimation of lipid profile by CHOD/PAP method.

Results: The mean age of the study participants was 34.7±2.9 years. The duration of smoking among the smokers was 5.4±2.9 years on an average. There was a significant increase in serum cholesterol levels (245.6±39.8 versus 155.8±15.2 mg/dl), serum triglycerides (217.3±42.2mg/dl versus 127.4±10.6), LDL (171.1±35.2 versus 85.7±15.1 mg/dl) and VLDL (43.5±10.5 versus 15.3±5.5mg/dl) among the smokers versus non-smokers. There was a significant (p<0.001) decrease in HDL levels among the smokers (30.8±3.4 mg/dl) when compared with the non-smokers (44.8±5.3 mg/dl). There was a highly significant difference between Framingham risk scores of smokers and non-smokers.

Conclusions: The study established that the lipid profile was deranged towards atherogenesis among the smokers when compared to the non-smokers which was reflected in the significant increase in risk as calculated by Framingham risk score.


Framingham risk scores, Lipid profile, Smokers and non-smokers

Full Text:



Howard G, Wagenknecht LE, Burke GL, Diez-Roux A, Evans GW, McGovern P, et al. Cigarette smoking and progression of atherosclerosis: The atherosclerosis risk in communities study. JAMA. 1998;279(2):119-24.

Benowitz NL, Fitzgerald GA, Wilson M, Zhang QI. Nicotine effects on eicosanoid formation and hemostatic function:comparison of transdermal nicotine and cigarette smoking. J Am Coll Cardiol. 1993;22:1159-67.

Tabas I, Williams KJ, Born J. Subendothelial lipoprotein retention as the initiating process in atherosclerosis update and therapeutic implications. Circulat. 2007;116:1832-44.

Stampfer MJ, Sacks FM, Salvini S, Willett WC, Hennekens CH. A prospective study of cholesterol, apolipoproteins, and the risk of myocardial infarction. New Eng J Med. 1991;325:373-81.

Witztum JL, Steinberg D. Role of oxidized low density lipoprotein in atherogenesis. J Clin Invest. 1991;88:1785-91.

Berliner JA, Heinecke JW. The role of oxidized lipoproteins in atherogenesis. Free Rad Bio Med. 1996;20(5):707-27.

Marangon K, Herbeth B, Lecomte E, Paul-Dauphin A, Grolier P, Chancerelle Y, et al. Diet, antioxidant status, and smoking habits in French men. The Am J Clinic Nutrit. 1998;67(2):231-9.

Burns DM. Epidemiology of smoking-induced cardiovascular disease. Prog Cardiovasc Dis. 2003;46(1):11-29.

Muscat JE, Harris RE, Haley NJ, Wynder EL. Cigarette smoking and plasma cholesterol. Am Heart J. 1991;121(1):141-7.

Simons LA, Simons J, Jones AS. The interactions of body weight, age, cigarette smoking and hormone usage with blood pressure and plasma lipids in an Australian community. Aus New Zeal J Med. 1984;14(3):215-1.

Benouwitz HL. Pharmacologic aspects of cigarette smoking and nicotine addiction. New Engl J Med 1998;319:318-0.

Stalder M, Pometta D, Suenram A. Relationship between plasma insulin levels and high density lipoprotein cholesterol levels in healthy men. Diabetol. 1981;21(6):544-8.

Reaven GM. Role of insulin resistance in human disease. Diab. 1988;37:595-607.

Rastogi R, Shrivastava SS, Mehrotra TN, Singh VS, Gupta MK. Lipid profile in smokers. J Assoc Physic India. 1989;37(12):764-6.

McCall MR, van den Berg JJ, Kuypers FA, Tribble DL, Krauss RM, Knoff LJ, et al. Modification of LCAT activity and HDL structure. New links between cigarette smoke and coronary heart disease risk. Arterios Thromb Vasc Bio. 1994;14:248-53.

Neki NS. Lipid profile in chronic smokers-a clinical study. J Ind Acad Clinic Med. 2002;3(1):51-4.

Witztum JL, Steinberg D. Role of oxidized low density lipoprotein in atherogenesis. J Clin Invest. 1991;88:1785-91.

Berliner JA, Heinecke JW. The role of oxidized low density lipoproteins in atherogenesis. Free Radic Biol Med. 1996;20:707-27.

Khurana M, Sharma D, Khandelwal PD. Lipid profile in smokers and tobacco chewers-a comparative study. J Assoc Physic India. 2000;48(9):895-7.